ArticleIntensive care medicine2008
High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats.
Article in Intensive care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Continuous Antithrombin III Infusion in a Clinically Relevant Sepsis Model.Shock (Augusta, Ga.) · 2026Article
- Article
- The regulation of T helper cell polarization by the diterpenoid fraction ofFrontiers in pharmacology · 2022Article
- Post-traumatic brain injury antithrombin III recovers Morris water maze cognitive performance, improving cued and spatial learning.The journal of trauma and acute care surgery · 2021Article
- Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats.Journal of thrombosis and haemostasis : JTH · 2020Article
- p38MAPK plays a pivotal role in the development of acute respiratory distress syndrome.Clinics (Sao Paulo, Brazil) · 2019Review
- Expression and functional characterization of two natural heparin-binding site variants of antithrombin.Journal of thrombosis and haemostasis : JTH · 2018Article
- Blockade of Extracellular High-Mobility Group Box 1 Attenuates Systemic Inflammation and Coagulation Abnormalities in Rats with Acute Traumatic Coagulopathy.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review.Expert review of clinical immunology · 2014Review
- Targeting HMGB1 in the treatment of sepsis.Expert opinion on therapeutic targets · 2014Review
- Effects of dexmedetomidine on early and late cytokines during polymicrobial sepsis in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2013Article
- Antithrombin III injection via the portal vein suppresses liver damage.World journal of gastroenterology · 2012Article
- The new vitamin E derivative, ETS-GS, protects against cecal ligation and puncture-induced systemic inflammation in rats.Inflammation · 2012Article
- Role of Apoptosis in Amplifying Inflammatory Responses in Lung Diseases.Journal of cell death · 2010Article
- High-dose antithrombin III prevents heat stroke by attenuating systemic inflammation in rats.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010Article
- Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.Cancer letters · 2010Article
- Year in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching.Intensive care medicine · 2010Article
- High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.Inflammation & allergy drug targets · 2010Review
- Role of Apoptosis in Amplifying Inflammatory Responses in Lung Diseases.Journal of cell death · 2010Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHigh mobility group box 1 (HMGB1) is an important factor in the development of sepsis. Previous work suggests that antithrombin III (ATIII) inhibits inflammation, but the mechanism of action is still poorly understood. DESIGN AND
settingProspective controlled animal study in a university laboratory. MATERIALS: Rats were randomly divided into a lipopolysaccharide (LPS)-induced sepsis control group and an ATIII-treated experimental group. Animals in the experimental group received a bolus of 250 units/kg of ATIII injected into the tail vein. MEASUREMENTS AND
resultsAnimals receiving high-dose ATIII (250 units/kg) had significantly improved lung histopathology and survival compared to the control rats. We measured serum and lung levels of various cytokines and HMGB1 at regular intervals from 0 to 12 h after the induction of sepsis and demonstrated lower HMGB1 levels over time in ATIII-treated animals. In an in vitro experiment, we stimulated the mouse macrophage cell line RAW 264.7 with LPS in the presence or absence of ATIII. Subsequent measurement of HMGB1 concentrations in the supernatant and cell signaling molecules in cell lysates revealed an ATIII dose-dependent decrease in HMGB1 release. Furthermore, inhibition of IkB and p42 phosphorylation was observed with the administration of ATIII, suggestive of downstream signaling pathways.
conclusionsHigh-dose ATIII decreases lung pathology and reduces mortality in a rat sepsis model. This finding may be mediated by the inhibition of HMGB1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.